Giulio Draetta, MD, PhD
Director, Institute for Applied Cancer Science and Professor of Genomic Medicine, The University of Texas
Dr. Draetta is currently Director, Institute for Applied Cancer Science, and Professor of Genomic Medicine, The University of Texas MD Anderson Cancer Center. He was the former Chief Research Business Development Officer, Dana Farber Cancer Institute; Former Deputy Director, Belfer Institute for Applied Cancer Science at DFCI. Former head of oncology drug discovery at Pharmacia and Merck. Scientific Advisor: Epitherapeutics, Forma Therapeutics, Blueprint Medicines, Taiho Pharmaceutical Co.
While at Cold Spring Harbor Laboratory, at EMBL Heidelberg and the European Institute of Oncology, Dr. Draetta spearheaded fundamental research in the biology of the eukaryotic cell division cycle and of DNA damage induced checkpoints. He was co-founder and head of research of Mitotix, Inc. At Pharmacia and Merck where he focused on the discovery and development of inhibitors of receptor tyrosine kinase signaling, cell division cycle inhibitors, novel cytotoxics, developmental pathway inhibitors, epigenetics and cancer metabolism drugs.
Christopher Kirk, PhD
President and Chief Scientific Officer, Co-Founder Kezar Life Sciences
Dr. Kirk is the is co-founder and current President and Chief Scientific Officer at Kezar Life Sciences. Prior to founding Kezar, Dr. Kirk was the Vice President of Research at Onyx Pharmaceuticals from April 2010 to April 2014. Dr. Kirk previously served as Director of Pharmacology and Biology at Onyx and at Proteolix, Inc. which was acquired by Onyx in 2009. At Proteolix, Dr. Kirk played a key role in the discovery and early development of the proteasome inhibitor, carfilzomib (Kyprolis®). Dr. Kirk received his B.S. degree in biochemistry from the University of California, Davis, and his Ph.D. degree in cellular and molecular biology from the University of Michigan.
Mansoor Raza Mirza, MD
Chief Oncologist at the Department of Oncology, Rigshopitalet – Copenhagen University Hospital, Denmark
Dr. Mirza has served as a member of our board of directors since October 2010. He has also served as a scientific consultant to us since 2010. Dr. Mirza is Chief Oncologist at the Department of Oncology, Rigshopitalet — the Copenhagen University Hospital, Denmark and Medical Director of Nordic Society of Gynaecological Oncology (NSGO).
Dr. Mirza is both a medical and radiation oncologist, with a primary focus in non-surgical treatment of gynecologic cancers. His key academic goals are to promote clinical research, international trial collaboration and education, and he has broad experience in clinical protocol development, trial conduct and clinical trial regulations.
Dr. Mirza is the author of several phase 1, 2 and 3 studies and serves as the chair of the Independent Data Safety Monitoring Committee of the OUTBACK trial, which is a large international cervical cancer trial. He is the senior author of national Danish guidelines for the management of endometrial, cervical, vulvar and non-epithelial ovarian cancers as well as of NSGO radio therapy guidelines for cervical and vulvar cancers.
His other current appointments include service as ESGO Council Member (European Society of Gynaecological Oncology), Executive Director of GCIG (Gynecologic Cancer InterGroup), Vice-Chairman of the Danish Gynecological Cancer Society, Founding Executive Member of the European Network of Gynecologic Oncology Trials Group and faculty member of the European Society of Medical Oncology and of the International Gynecologic Cancer Society. He also serves on the board of directors of Sera Prognostics, Inc., a private biopharmaceutical company.
He holds a M.D., Diploma in Surgery and Diploma in Clinical Oncology from the Pirogov Moscow State Medical Institute as well as post-graduate education and certification in radiation and medical oncology from the University of Southern Denmark.
Michael Savona, MD, FACP
Associate Professor of Internal Medicine, and Director of Early Therapeutics, Hematologic Malignancies at Vanderbilt University
Dr. Savona is currently Associate Professor of Internal Medicine, and Director of Early Therapeutics, Hematologic Malignancies at Vanderbilt University.
He recently served as Director, Leukemia Research, at Sarah Cannon Research Institute where he spearheaded efforts to develop a Phase I program in Hematology.
He has been the Principal Investigator on dozens of clinical studies, and has been the lead investigator on studies of variety of novel compounds in hematologic malignancies. He has been involved medical research for 20 years, and has published extensively in major academic journals including Nature Medicine, Blood, Cell Stem Cell, JAMA, and Nature Cancer Reviews.
He is board certified in medical oncology, hematology and internal medicine, and is an elected fellow of the American College of Physicians. Dr. Savona obtained his bachelor’s degree in philosophy from Davidson College and medical degree at Wake Forest University School of Medicine in Winston-Salem, North Carolina.
Sharon Shacham, PhD, MBA
President and Chief Scientific Officer
Dr. Shacham founded Karyopharm in 2008 and has served as our Chief Scientific Officer and President of Research and Development since December 2012. From 2010 to 2012, Dr. Shacham served as our Chief Scientific Officer and Head of Research and Development, and prior to that, as our President and Chief Executive Officer. Dr. Shacham has led our scientific progress since inception.
Prior to joining Karyopharm, Dr. Shacham served as Senior Vice President of Drug Development at Epix Pharmaceuticals, Inc., and Director, Algorithm and Software Development at Predix Pharmaceuticals Inc., which merged into Epix Pharmaceuticals in 2006, and where she led the company’s efforts in GPCR modeling, computational chemistry, lead optimization and development of clinical trials.
Dr. Shacham holds a Bachelor of Science in Chemistry, along with a Doctor of Philosophy and a Master of Business of Administration from Tel Aviv University.